Share on StockTwits

Agios Pharmaceuticals (NASDAQ:AGIO) COO John Duncan Higgons unloaded 5,000 shares of the stock in a transaction dated Tuesday, August 26th. The shares were sold at an average price of $45.05, for a total transaction of $225,250.00. Following the completion of the transaction, the chief operating officer now directly owns 176,090 shares of the company’s stock, valued at approximately $7,932,855. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

A number of analysts have recently weighed in on AGIO shares. Analysts at Citigroup Inc. initiated coverage on shares of Agios Pharmaceuticals in a research note on Tuesday, July 1st. They set a “buy” rating and a $58.00 price target on the stock. Analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Monday, June 16th. They now have a $60.00 price target on the stock, up previously from $55.00.

Shares of Agios Pharmaceuticals (NASDAQ:AGIO) traded down 0.95% on Thursday, hitting $45.01. 199,576 shares of the company’s stock traded hands. Agios Pharmaceuticals has a one year low of $15.77 and a one year high of $50.37. The stock’s 50-day moving average is $39.43 and its 200-day moving average is $39.50. The company’s market cap is $1.551 billion.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.54) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.41) by $0.13. The company had revenue of $8.41 million for the quarter, compared to the consensus estimate of $11.00 million. During the same quarter last year, the company posted ($2.80) earnings per share. Agios Pharmaceuticals’s revenue was up 33.3% compared to the same quarter last year. On average, analysts predict that Agios Pharmaceuticals will post $-1.94 earnings per share for the current fiscal year.

Agios Pharmaceuticals, Inc is a biopharmaceutical company. The Company is intend to apply its deep understanding of metabolism, coupled with the Company’s ability to create medicines that can inhibit or activate metabolic enzymes, to fundamentally change the way cancer and inborn errors of metabolism (NASDAQ:AGIO) are treated.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.